Last updated 16 days ago
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
400 patients around the world
Available in Brazil, United States, Mexico, Argentina
Hoffmann-La Roche
18Research sites
400Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
Recruiting
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Recruiting
Hospital Provincial del Centenario - Rosario, Santa Fe
Recruiting
Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja
Recruiting
Fundación CENIT para la Investigación en Neurociencias
Recruiting
Centro Oncológico Korben
Recruiting
Instituto de Oncología de Rosario - IOR
Recruiting
Sanatorio Allende (Nueva Córdoba)
Recruiting
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Recruiting
Hospital De Base de São José do Rio Preto - CIP São José
Recruiting
StudyINAVO121
SponsorHoffmann-La Roche
Conditions
Breast Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05646862
